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Abstract
BACKGROUND: Regular exercise is recommended to improve outcomes in patients with heart failure.
Exercise is known to decrease inflammation and thought to decrease myocardial stress; however, studies of
exercise in heart failure have had mixed results on levels of N-terminal pro-B-type natriuretic peptide (NT-
proBNP) and high-sensitivity C-reactive protein (hsCRP). A multimarker analysis may help to identify
distinct subgroups of patients who respond to exercise. Our primary study objective was to identify common
and distinct patterns of change in hsCRP and NT-proBNP and to quantify the influence of exercise therapy on
the observed patterns of change.
METHODS AND RESULTS: NT-proBNP and hsCRP were assessed in a random sample of 320 participants
from the biomarker substudy of HF-ACTION, a randomized clinical trial of exercise training versus usual care
in patients with stable and chronic heart failure. Growth mixture modeling was used to identify unique
biomarker patterns over 12 months. Three statistically independent and clinically meaningful biomarker
patterns of NT-proBNP and hsCRP were identified. Two patterns were combined and compared with the
"low/stable" pattern, which was characterized by the lowest levels of NT-proBNP and hsCRP over time.
Participants who were taking a loop diuretic and had hypertension or ischemic etiology were ∼2 times as likely
to be in the "elevated/worsening" biomarker pattern. Participants randomized to the exercise intervention
were less likely to be in the elevated/worsening pattern of NT-proBNP and hsCRP (relative risk ratio 0.56,
95% confidence interval 0.32-0.98; P = .04).
CONCLUSIONS: Exercise therapy was protective for reducing the frequency of membership in the elevated/
worsening biomarker pattern, indicating that exercise may be helpful in delaying the progression of heart
failure.
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Abstract
Background—Regular exercise is recommended to improve outcomes in patients with heart 
failure. Exercise is known to decrease inflammation and thought to decrease myocardial stress; 
however, studies of exercise in heart failure have had mixed results on levels of N-terminal pro-B-
type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hsCRP). A multi-
marker analysis may help identify distinct subgroups of patients who respond to exercise. The 
primary study objective was to identify common and distinct patterns of change in hsCRP and NT-
proBNP and quantify the influence of exercise therapy on the observed patterns of change.
Methods and Results—NT-proBNP and hsCRP were assessed in a random sample of 320 
participants from the biomarker sub-study of HF-ACTION, a randomized clinical trial of exercise 
training versus usual care in patients with stable and chronic heart failure. Growth mixture 
modeling was used to identify unique biomarker patterns over 12-months. Three statistically 
independent and clinically meaningful biomarker patterns of NTproBNP and hsCRP were 
identified. Two patterns were combined and compared to the “low/stable” pattern, which was 
characterized by the lowest levels of NT-proBNP and hsCRP over time. Participants who were 
taking a loop diuretic, had hypertension or ischemic etiology were about two times as likely to be 
in the “elevated/worsening” biomarker pattern. Participants randomized to the exercise 
intervention were less likely to be in the elevated/worsening pattern of NT-proBNP and hsCRP 
(relative risk ratio: 0.56, CI: 0.32–0.98, p=0.04).
Conclusions—Exercise therapy was protective for reducing the frequency of membership in the 
elevated/worsening biomarker pattern, indicating that exercise may be helpful in delaying the 
progression of heart failure.
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Exercise therapy is considered a safe non-pharmacological intervention to improve 
functional capacity1 and clinical outcomes2 for adults with heart failure. Moderate exercise 
routines (3 to 7 metabolic equivalent hours per week) are associated with a decreased risk of 
clinical events.3 Physiologically, in patients with heart failure exercise training improves 
myocardial contractility, perfusion, endothelial dysfunction,4,5 angiogenesis,6 and coronary 
and peripheral skeletal vessel dilation.7 A challenge to the broad implementation of exercise 
training in heart failure is physiologic heterogeneity in response to exercise. That is, some 
patients respond to exercise therapy with reductions in peripheral hypoxia,8 local 
inflammation9 and resting heart rate,10 while others do not. Accordingly, the primary aim of 
this study was to identify common and distinct patterns of change in serum biomarkers of 
systemic inflammation and myocardial stress among adults with stable heart failure who 
participated in an exercise trial. The secondary aim of this study was to identify socio-
demographic and clinical predictors of the most unfavorable patterns of change in 
biomarkers of systemic inflammation and myocardial stress. We hypothesized that exercise 
therapy would be associated with more favorable patterns of change in biomarkers over 
time.
Methods
Study population
This was a secondary analysis of data from a random selection of 320 participants in the 
biomarker sub-study of Heart Failure: A Controlled Trial Investigating Outcomes of 
Exercise Training (HF-ACTION) randomized controlled trial. The full study design has 
been published previously.2,11 Briefly, HF-ACTION was a multicenter, randomized 
controlled trial designed to examine long-term safety and efficacy of aerobic exercise 
training in a large sample of medically stable, chronic outpatients with heart failure. 
Enrollment criteria included reduced left ventricular ejection fraction (LVEF) of 35% or 
less, New York Heart Association (NYHA) class II to IV and willingness to undergo 
exercise training. Patients were excluded if they could not exercise, were already habitual 
exercisers or had a cardiovascular event in the preceding 6 weeks. Participants were 
randomized from 82 centers within the United States, Canada and France from 2003–2007 
to a usual care or aerobic exercise-training group. The intervention entailed 36 supervised 
sessions followed by home-based training.
Participants performed a maximal exercise test with gas exchange measurements on a 
treadmill, using the modified Naughton protocol, or a cycle ergometer, using a 10-Watt/min 
ramp protocol.12 Functional exercise capacity was measured at baseline by peak oxygen 
consumption (mL/kg/min).11 Blood samples were collected from a peripheral vein into 
EDTA-containing tubes, centrifuged immediately and stored at −70°C. 11 All samples were 
obtained on the same day but prior to exercise testing at the baseline, 3-month, and 12-
month visits.13 Assays for all biomarkers were performed using commercially available 
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assays (Roche Diagnostics, Inc.) at the Duke University central core laboratory.13 Socio-
demographic and clinical history characteristics were self-reported at baseline and patients 
completed the EuroQol-5D as a measure of baseline health status.11
The HF-ACTION randomized controlled trial was approved by all relevant institutional 
review boards at the participating centers and the coordinating center.11 This study was also 
approved by institutional review boards at the University of Pennsylvania and Duke 
University.
Biomarker measures
High-sensitivity C-reactive protein (hsCRP) (mg/L) was selected as a marker of 
inflammation because it is associated with heart failure severity.14,15 N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) (pg/mL) was selected as a marker of myocardial stress and 
hemodynamic congestion because it is released in response to ventricular dilation, 
hypertrophy and wall tension16 and increases with the severity of ventricular dysfunction.17 
NT-proBNP is also used routinely in the clinical management of patients with heart failure 
as an indicator of heart failure progression.13,18,19 In addition, standard, reproducible and 
cost-effective assays are available for both biomarkers, making them useful for 
prognostication.20,21 Both assays were also available in the HF-ACTION repository. 
Troponin was initially considered for this analysis, but was not included because there were 
concerns about the analytic sensitivity and lack of variability (zero-inflation) of the assay.
Statistical Analysis
In the preliminary analysis, descriptive statistics of frequency, central tendency and 
dispersion over time were used to describe hsCRP and NT-proBNP independently. 
Consistent with previous HF-ACTION publications,13,22 raw values of NT-proBNP and 
hsCRP were log-transformed to approximate normality. Mean values of ln(hsCRP) and 
ln(NT-proBNP) values were compared between the exercise training and usual care groups 
using analysis of covariance (ANCOVA), controlling for baseline biomarker values and 
treatment allocation. ANCOVA models that used the baseline biomarker value as the single 
covariate were used to test for differences between the usual care and intervention groups’ 
mean ln(NTproBNP) and ln(hsCRP) values at baseline, 3-and 12-months, respectively.
The primary aim of this study was to identify common and distinct patterns of change in 
ln(hsCRP) and ln(NT-proBNP). Growth mixture modeling was used to identify subgroups 
of patients whose biomarker profiles differed at enrollment (i.e. intercepts) and/or had 
unique patterns of change over time (i.e. slopes). Common principles of model 
specification23 were used including: the significance of the adjusted and non-adjusted Lo-
Mendell-Rubin likelihood ratio test,24 entropy (close to 100%), the proportion of sample in 
each pattern (>=5%), and posterior probabilities (close to 1).25 Individual growth mixture 
models for ln(NT-proBNP) and ln(hsCRP) were identified and then combined in a single 
model, and each participant was assigned a “most likely pattern” based on conditional 
probabilities. Due to the small size of one observed pattern, two related patterns were 
combined for further analyses. Baseline characteristics of the two patterns were described 
using medians (interquartile ranges) or means (SD) and frequencies (proportions) where 
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appropriate. Unadjusted differences between the biomarker patterns were quantified using t-
test, χ2 analysis or one-way analysis of variance. Differences in peak oxygen consumption 
between the two patterns were compared to better understand the clinical relevance of the 
observed patterns.
Socio-demographic and clinical factors that influenced the likelihood of fitting in the 
unfavorable pattern were identified using a model comparison approach26 including: 
bivariate analyses with the outcome (p<0.05) and forward and backwards stepwise 
multivariable logistic regression modeling. Logistic regression was used to identify 
predictors of observed patterns; results are reported in adjusted odds ratios (ORs), 95% 
confidence intervals (CIs) and corresponding p-values. Model fit was compared using: χ2 
likelihood ratio, pseudo R2, AIC, and BIC tests. Mplus (version v.7.0, Los Angeles, CA) 
was used for all growth mixture modeling and all other analyses were conducted in StataMP 
v11.2 (College Station, Texas).
Results
Baseline characteristics for this sample (n=320) are reported in Table 1. Overall, the median 
age was 58 years, the majority of the sample was male (73%), NYHA class II (71%) with a 
median left ventricular ejection fraction (LVEF) of 24 percent. Just over one-third of 
participants had a history of diabetes (34%) or previous myocardial infarction (39%) and 
approximately two-thirds had hypertension (60%). The vast majority of participants in this 
study were treated with evidence-based therapies, including over 95% on an angiotensin-
converting-enzyme inhibitor or angiotensin II receptor blocker and 93% on a beta-blocker. 
Almost 50% of the sample was on a statin medication and almost 14% had an implanted 
biventricular pacemaker.
Baseline socio-demographic and clinical characteristics were compared between the original 
parent cohort and this subgroup. In general, this subpopulation was representative of the 
parent cohort, but there were significant differences in the proportions of patients in NYHA 
class II at baseline in this sample versus the total population (71% versus 63%, p=0.008). 
There were no statistically significant differences between the means in the usual care and 
intervention groups for ln(NT-proBNP) between baseline and 3 months (p=0.499) or 
baseline and 12 months (p=0.471). There were also no differences in ln(hsCRP) from 
baseline to 3 months (p=0.168) or baseline to 12 months (p=0.193) between the usual care 
and intervention groups (Figure 1). Thus, growth mixture modeling was used to further 
identify and describe potential underlying patterns.
Identification of Multiple Patterns of Change in Biomarkers Over Time
Three statistically independent and clinically meaningful biomarker patterns of NTproBNP 
and hsCRP were identified (entropy =0.79, Lo-Mendell Rubin adjusted likelihood ratio test 
p=0.02, and average posterior probabilities = 0.87–0.93 all indicating a good model 
solution) (Figure 2). Based on the observed characteristics of NT-proBNP and hsCRP, the 
first and smallest pattern of change (n=15 [5%]; average posterior probability was 0.90) had 
the highest levels of NT-proBNP at baseline that did not change over time (p=0.827) and 
hsCRP increased significantly over 12 months (p<0.001). The second pattern of change 
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(n=197 [61%]; average posterior probability = 0.92) was characterized by lower levels of 
NT-proBNP and hsCRP at baseline, and there were significant declines in both NT-proBNP 
(p=0.006) and hsCRP (p<0.001) over the course of 12-months. The third pattern (n=108 
[34%]; average posterior probability = 0.87) had higher hsCRP (p<0.001) and similar NT-
proBNP levels (p=0.885) compared with the second pattern at baseline and improvements in 
hsCRP over the 12-month follow-up period (p=0.017). Due to the small size of the first 
pattern, the first and third patterns were combined and labeled “elevated/worsening” 
(n=123). On average, peak oxygen consumption was lower at baseline among patients with 
the elevated/worsening biomarker pattern compared with those with the low/stable 
biomarker pattern and this difference held over time (Figure 3).
Identification of Biomarker Pattern Determinants—Determinants of the elevated/
worsening biomarker pattern are presented in Table 2, (model χ2=67.31, p<0.001, pseudo 
R2=16.5%). The odds of being in the elevated/worsening pattern were almost two times 
higher for patients with ischemic etiology, hypertension or for those on loop diuretics and 
9% higher for each unit increase in body mass index. The variables in the model offer fair 
prognostication for the elevated/worsening pattern (area under the curve: 0.716). Having 
diabetes was associated with reduced odds of having the elevated/worsening biomarker 
pattern. Finally, participants who were randomized to the exercise group were much less 
likely than those in the usual care group to have the elevated/worsening biomarker pattern.
Discussion
In this random sample of 320 participants from the biomarker sub-study of the HF-ACTION 
trial, we observed two clinically relevant patterns of change in biomarkers of myocardial 
stress and systemic inflammation. One pattern was characterized by elevated myocardial 
stress and inflammation and the other was characterized by lower myocardial stress and 
decreasing inflammation over 12-months. Traditional markers of disease severity were 
associated with being in the elevated/worsening biomarker pattern. Exercise therapy 
provided a protective effect for not being associated with the elevated/worsening biomarker, 
which supports the potential for exercise therapy to contribute to slowing the progression of 
heart failure.27
The finding that there are no mean differences in mean ln(NT-proBNP) or ln(hsCRP) over 
time between the exercise and usual care group are consistent with the study by Ahmad and 
colleagues that used a sample of 928 participants from the HF-ACTION study.22 Ahmad 
and colleagues reported that exercise training (measured by volume of exercise) was not 
associated with numerical decreases in NT-proBNP and hsCRP from baseline to 3-
months.22 In an effort to further explain the relationship between these biomarkers (NT-
proBNP and hsCRP) and exercise therapy, this study used growth mixture modeling to 
identify distinct multi-marker biomarker patterns. This methodology is especially relevant 
for a heterogeneous heart failure population, where being able to identify distinct patterns is 
clinically informative. When NT-proBNP and hsCRP were combined into distinct multi-
marker patterns, we identified a small third pattern with rising hsCRP over 12-months. The 
characteristics of this pattern may partially explain why they did not find a statistically 
significant mean reduction in hsCRP in the exercise therapy group compared to usual care. 
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The findings reported here are consistent with results from the Cardiovascular Health Study 
(CHS), in which deFilippi and colleagues reported a protective effect of moderate physical 
activity on the risk of developing heart failure, neurohormonal activation (measured by NT-
proBNP) and cardiac injury (measured by Troponin T).28
When comparing the elevated/worsening and low/stable patterns, participants randomized to 
the exercise therapy intervention were less likely to have the elevated/worsening pattern. 
Hypertension was associated with two times the risk of being in the elevated/worsening 
compared to low/stable pattern, along with other measures of severity—being on a loop 
diuretic or having heart failure of ischemic etiology. Many patients with reduced renal 
function also have hypertension, which can cause left ventricular hypertrophy and elevated 
natriuretic peptides.29 Hypertension and hsCRP have also been associated in other studies 
due to shared mechanisms of oxidative stress and endothelial dysfunction.30 Specifically, 
hsCRP is known to attenuate nitric oxide production and decrease endothelial nitric oxide 
synthase expression leading to vasoconstriction and atherothrombosis.20 The association 
between elevated hsCRP and hypertension is consistent across multiple racial and ethnic 
groups.31,32
Higher BMI was associated with the elevated/worsening biomarker pattern. An inverse 
relationship between BMI and NT-proBNP has been reported in many other studies,33–37 
one theory is that there is increased clearance of NT-proBNP by type C natriuretic peptide 
receptors on adipocytes.38 In obese patients, natriuretic peptides are still routinely used for 
diagnostic purposes, but at lower cutoff levels.36
Diabetes was also associated with a lower risk of being in the elevated/worsening pattern. 
This may be explained by a higher proportion of diabetic patients being on a statin 
medication compared to non-diabetics (59% versus 43%). Statins are associated with 
reduced hsCRP in diabetic patients.39 The apparently protective effect of diabetes may be 
due to chance, or it might be related to the fact that diabetic participants were less likely than 
non-diabetic participants to have ischemic etiology (44% versus 56%). However, controlling 
for statin use and ischemic vs. non-ischemic etiology in post-hoc models did not change the 
strength of the relationship between diabetes and the risk of having the hazardous patterns of 
change in these biomarkers. More research is needed to further explore associations among 
diabetes and other comorbidities in heart failure and the systemic inflammatory and 
myocardial stress responses to exercise.
Strengths and Limitations
One potential limitation of this study is its generalizability because it was conducted on a 
random sample of the biomarker sub-study chosen from those with nearly complete data. 
Although it is unlikely that our results were solely a function of sample selection, it is 
possible that if this analysis were done on in the entire dataset that the results would be 
different. It should be noted that this random sample was representative of the larger HF-
ACTION trial population. Although we successfully identified statistically distinct 
biomarker subgroups and corresponding predictors, further testing in a larger sample may 
increase the precision of the estimates. Given that the measure of exercise was 
randomization to the exercise intervention, rather than quantity, it is likely that the protective 
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effect of exercise would be stronger if adherence were accounted for. Another limitation is 
that we had data at three time points and this is the minimum number of data points for 
growth mixture modeling. Further description of the patterns, including possible curvilinear 
or nonlinear growth patterns would only be possible with additional measurement points. 
The final limitation is that the exercise therapy group tended to have lower NT-proBNP at 
baseline, though this difference was not statistically significant (p=0.083). This slight 
imbalance at randomization is unlikely to account for the protective effect of exercise 
therapy reported in this study.
The growth mixture modeling analytic approach was a major strength of this study because 
it allowed for the identification of previously unobserved biomarker patterns of change. 
Though traditionally biomarkers have been considered individually,16 multi-marker 
strategies are now recommended to improve risk stratification and prediction in chronic 
heart failure.16,40,41 As such, it is a useful analytic tool for helping to explain the 
heterogeneity in response to exercise therapy that is common among patients with heart 
failure. Another strength of this study was that it built on the results of the Ahmad study,22 
demonstrating how different types of biomarker analyses can help to explain how exercise 
may be able to slow or prevent the progression of heart failure.27
There are many related avenues for future research around exercise and heart failure, 
including further elucidation of mechanisms of benefit, identifying which biomarkers are 
modified by exercise, quantifying the dose of exercise needed to achieve a benefit, and 
identifying ways to engage heart failure patients in exercise.27 There is also a strong need to 
identify different exercise regimens for patients with heart failure and prevalent comorbid 
conditions such as type 2 diabetes. In the future, multi-marker biomarker analyses of 
exercise interventions may also be able to clarify which patients can be expected to benefit 
from exercise by demonstrating the mechanism by which exercise slows the progression of 
heart failure.27
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Highlights
• We model two biomarkers of hsCRP and NT-proBNP using growth mixture 
modeling.
• Growth mixture models are well suited for identifying variations in therapeutic 
responses in important patient subgroups in a heterogeneous syndrome like heart 
failure.
• Multi-marker analytic strategies can provide more information than single 
biomarker analyses alone.
• Exercise therapy may helpful for delaying the progression of heart failure.
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Figure 1. 
This figure reports no statistically significant change in mean ln(NT-proBNP) and 
ln(hsCRP) between baseline and 12-months with 95% confidence intervals over time 
between the usual care and exercise training groups. P-values reported are from ANCOVA 
models adjusted for baseline biomarker values and treatment allocation.
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Figure 2. 
Three statistically independent and clinically meaningful biomarker patterns of 
ln(NTproBNP) and ln(hsCRP) are presented. Patterns 1 and 3 were combined and labeled 
“elevated/worsening” and compared to Pattern 2, labeled “low/stable.” For economy of 
presentation, error bars were not included in this figure.
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Figure 3. 
Differences in changes in peak oxygen consumption are presented comparing elevated/
worsening (dotted line) and low/stable (solid line) patterns. Differences in the intercept (i) 
indicate that baseline values of peak oxygen consumption were higher in the low/stable 
pattern at baseline relative to the elevated/worsening pattern. Differences in the slope (s) 
indicate that the change over time was statistically significant (p=0.020) comparing the 
elevated/worsening and low/stable patterns over one-year.
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Table 1a
Baseline demographic and clinical characteristics by biomarker pattern at baseline
Variables (%, median/IQR) Overall (N=320) Low/stable (n=197) Elevated/Worsening (n=123) p-value
 Usual care 157 (49) 92 (47) 65 (53)
 Exercise training 163 (51) 105 (53) 58 (47)
Age 58 (51, 67) 59 (51, 69) 57 (52, 65) 0.18
Female sex 86 (27) 48 (24) 38 (31) 0.20
Race (n=315) 0.53
  Black or Other 112 (36) 66 (34) 46 (38)
  White 203 (64) 127 (66) 76 (62)
New York Heart Association class 0.14
  II 226 (71) 145 (74) 81 (66)
  III/IV 94 (29) 52 (26) 42 (34)
Ischemic etiology 167 (52) 96 (49) 71 (58) 0.12
Diabetes mellitus 108 (34) 69 (35) 39 (32) 0.54
Previous myocardial infarction 126 (39) 80 (41) 46 (37) 0.57
Hypertension 194 (60) 113 (57) 81 (66) 0.13
Atrial fibrillation 64 (20) 36 (18) 28 (23) 0.33
Clinical values
 Left ventricular ejection fraction 24 (21, 30) 25 (21, 30) 24 (20, 30) 0.46
 Systolic blood pressure, mm Hg 112 (102, 130) 113 (102, 130) 110 (100, 130) 0.41
 Diastolic blood pressure, mm Hg 70 (61, 80) 70 (60, 80) 70 (62, 78) 0.98
 Sodium, mEq/L 139 (138, 141) 140 (138, 141) 139 (137, 141) 0.68
 Creatinine, mg/dL, (n=294) 1.2 (1.0, 1.5) 1.1 (1.0, 1.4) 1.2 (1.0, 1.5) 0.13
 BUN, mg/dL, (n=292) 20 (15, 27) 19 (15, 25) 22 (15, 31) 0.09
 Beck Depression Index, (n=318) 8 (4, 15) 7 (4, 15) 9 (4, 15) 0.13
Data are complete for all 320 participants unless otherwise indicated, p-values indicate difference in mean values between biomarker subgroups for 
continuous variables.
Abbreviations: IQR: interquartile range; BUN: blood urea nitrogen
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Table 1b
Medication use, functional status and EuroQol-5D by biomarker pattern at baseline
Baseline use of medications and devices (%)
 ACE inhibitor or ARB 305 (95) 189 (96) 116 (94) 0.50
 B-blocker 299 (93) 183 (93) 116 (94) 0.62
 Loop diuretic 241 (75) 135 (69) 106 (86) 0.001*
 Statin 156 (49) 98 (50) 58 (47) 0.65
 ICD 118 (37) 63 (32) 55 (45) 0.02*
 Pacer 61 (19) 33 (17) 28 (23) 0.18
 Biventricular pacemaker 44 (14) 20 (10) 24 (20) 0.02*
Functional measures (median, IQR)
 PkV02, mL/kg/min 15.2 (12.2, 17.8) 15.6 (13.1, 18.2) 13.5 (11.3, 16.9) 0.001*
 Body mass index, kg/m2 30 (26, 35) 29 (25, 33) 32 (28, 38) <0.001*
 6 min walk, m (n=312) 384.0 (314.9, 440.2) 384.8 (320.0, 441.9) 383.0 (306.3, 435.9) 0.26
EuroQol-5D (%)
Question 4: Pain/Discomfort (n=317)
 No pain or discomfort 149 (47) 102 (52) 41 (39) 6 (40)
 Moderate pain 161 (51) 90 (46) 62 (59) 9 (60)
 Extreme pain 7 (2.2) 4 (2.0) 3 (28) 0 (0)
Question 5: Anxiety (n=318)
 Not anxious 187 (59) 118 (61) 62 (57) 7 (47)
 Moderately/Extremely anxious 131 (41) 77 (39) 46 (43) 8 (53)
Data are complete for all 320 participants unless otherwise indicated, p-values indicate difference in mean values between biomarker subgroups for 
continuous variables.
Abbreviations: ACE: angiotensin-converting-enzyme; ARB: angiotensin II receptor blocker; ICD: implantable cardioverter-defibrillator; IQR: 
interquartile range; PkV02: Peak oxygen consumption
*
p-values are significant (<0.05) between the biomarker patterns
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Table 2
Predictors of the “elevated/worsening” biomarker pattern
Variable Odds Ratio 95% Confidence Interval p-value
Exercise group 0.56 0.32 – 0.98 0.04
Ischemic etiology 1.93 1.03 – 3.65 0.04
Loop diuretic 2.32 1.16 – 4.63 0.02
Hypertension 2.00 1.10 – 3.63 0.02
Body mass index 1.09 1.04 – 1.14 <0.01
Diabetes 0.49 0.27 – 0.90 0.02
Peak oxygen consumption (mL/kg/min) 0.92 0.86 – 1.00 0.06
Factors included in the models included: randomization to the exercise intervention or usual care, gender, race, age, heart failure etiology, baseline 
peak oxygen consumption, body mass index, pain or anxiety (assessed with EuroQol-5D), diabetes, hypertension, taking a loop diuretic, 
implantation of a pacemaker, bi-ventricular pacer or implantable cardioverter-defibrillator, treatment with an angiotensin-converting-enzyme 
inhibitor or angiotensin II receptor blocker and beta-blockers.
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